Skip to main
VTVT

vTv Therapeutics (VTVT) Stock Forecast & Price Target

vTv Therapeutics (VTVT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

vTv Therapeutics Inc has a promising financial outlook primarily due to its innovative clinical pipeline, particularly with cadisegliatin (TTP399), which is positioned as the only oral adjunctive therapy in late-stage development for type 1 diabetes (T1D). An increase in the estimated peak market penetration from 20% to 25% significantly enhances the company's risk-adjusted discounted cash flow (DCF) valuation and reflects a growing long-term conviction in the potential of cadisegliatin for treating T1D and potentially type 2 diabetes (T2D). Positive key metrics from ongoing studies, including management's reviews and insights from related research, bolster confidence in the clinical success of their drug candidates and their ability to capture substantial market share amid a growing demand for more convenient diabetes treatments.

Bears say

vTv Therapeutics faces significant challenges due to the historical issues seen with first-generation glucokinase activators (GKAs), which have consistently demonstrated problems such as excess hypoglycemia, worsening lipid profiles, and diminishing efficacy over time, leading to increased safety concerns. The company’s lead candidate, cadisegliatin (TTP399), aims to address these limitations, yet it remains in late-stage development and is subject to risks associated with slower patient enrollment and potentially disappointing safety and efficacy outcomes. Additionally, with nearly 80% of adults with type 1 diabetes failing to meet key glucose control goals, there exists a fundamental clinical ceiling for improved therapeutic outcomes, which poses an ongoing risk to vTv Therapeutics' commercial prospects.

vTv Therapeutics (VTVT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About vTv Therapeutics (VTVT) Forecast

Analysts have given vTv Therapeutics (VTVT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, vTv Therapeutics (VTVT) has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

vTv Therapeutics (VTVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.